Chemotherapy protocol definition form | Download Scientific Diagram
Pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy in locally advanced breast cancer (registration number: ChiCTR1900023052) | Scientific Reports
Pregnancy-Associated Breast Cancer
Chemotherapy Protocol
Neoadjuvant Chemotherapy Considerations in Triple-Negative Breast Cancer
PDF) Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel (Dose Dense AC Followed by T) Regimen for Breast Cancer
Four cycles of docetaxel and cyclophosphamide as adjuvant chemotherapy in node negative breast cancer: A real-world study - ScienceDirect
Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial - The Lancet Regional Health – Western Pacific
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Frontiers | Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review
National Surgical Adjuvant Breast and Bowel Project (NSABP)
Chemotherapy for Uterus Cancer
Cancers | Free Full-Text | Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine
SWOG S 0800 ( NCI CDR 0000636131 ) : addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response ( pCR ) rates in inflammatory or locally
Dose-dense chemotherapy for breast cancer: what does the future hold? | Future Oncology
Dose-dense chemotherapy for breast cancer: what does the future hold? | Future Oncology
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
The Red Devil Chemo: Tips for Managing Side Effects
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Update on systemic treatment for newly diagnosed inflammatory breast cancer - ScienceDirect
Phase 2 Study of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Eribulin Mesylate With or Without Prophylactic Growth Factor for Adjuvant Treatment of Early-Stage Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer -
HER2-Targeted Therapy for Early-Stage Breast Cancer: A Comprehensive Review
Standardizing Chemotherapy Regimen Nomenclature: A Proposal and Evaluation of the HemOnc and National Cancer Institute Thesaurus Regimen Content | JCO Clinical Cancer Informatics
Chemotherapy regimens for breast cancer. | Download Table
